Sirtuin 2 inhibitors rescue α-synuclein-mediated toxicity in models of Parkinson's disease

Science

Volumn 317, Issue 5837, 2007, Pages 516-519

  Outeiro, Tiago Fleming ^a,b   Kontopoulos, Eirene ^c   Altmann, Stephen M ^b   Kufareva, Irina ^d   Strathearn, Katherine E ^e   Amore, Allison M ^b   Volk, Catherine B ^e   Maxwell, Michele M ^b   Rochet, Jean Christophe ^e   McLean, Pamela J ^a,b   Young, Anne B ^b   Abagyan, Ruben ^d   Feany, Mel B ^c   Hyman, Bradley T ^a,b   Kazantsev, Aleksey G ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

^e PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGK 2; ALPHA SYNUCLEIN; PROTEIN INHIBITOR; SIRTUIN; SIRTUIN 2; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ENZYME; FLY; INHIBITION; INHIBITOR; MODEL; NERVOUS SYSTEM DISORDER; RNA; TOXICITY;

AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DOPAMINERGIC NERVE CELL; DROSOPHILA; DRUG STRUCTURE; HELA CELL; HUMAN; HUMAN CELL; IC 50; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN FUNCTION; STRUCTURE ANALYSIS; TRANSGENIC ANIMAL;

ACETYLATION; ALPHA-SYNUCLEIN; ANIMALS; ANIMALS, GENETICALLY MODIFIED; CELL DEATH; CELL LINE, TUMOR; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DROSOPHILA MELANOGASTER; FURANS; HUMANS; MODELS, MOLECULAR; NEURONS; PARKINSON DISEASE; PROTEIN CONFORMATION; QUINOLINES; RATS; RNA, SMALL INTERFERING; SIRTUINS; TRANSFECTION; TUBULIN;

EID: 34547599329     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1143780     Document Type: Article

References (26)

1. M. G. Spillantini et al., Nature 388, 839 (1997).
2. A. B. Singleton et al., Science 302, 841 (2003).
3. G. Blander, L. Guarente, Annu. Rev. Biochem. 73, 417 (2004).
4. E. Kontopoulos, J. D. Parvin, M. B. Feany, Hum. Mol. Genet. 15, 3012 (2006).
5. B. J. North, B. L. Marshall, M. T. Borra, J. M. Denu, E. Verdin, Mol. Cell 11, 437 (2003).
6. B. Heltweg et al., Cancer Res. 66, 4368 (2006).
7. A. Vaquero et al., Genes Dev. 20, 1256 (2006).
8. B. Langley, J. M. Gensert, M. F. Beal, R. R. Ratan, Curr. Drug Targets CNS Neurol. Disord. 4, 41 (2005).
9. R. A. Bodner et al., Proc. Natl. Acad. Sci. U.S.A. 103, 4246 (2006).
10. R. Abagyan, M. Totrov, D. Kuznetsov, J. Comput. Chem. 15, 488 (1994).
11. J. L. Avalos, K. M. Bever, C. Wolberger, Mol. Cell 17, 855 (2005).
12. J. Klucken, Y. Shin, E. Masliah, B. T. Hyman, P. J. McLean, J. Biol. Chem. 279, 25497 (2004).
13. T. F. Outeira et al., Biochem. Biophys. Res. Commun. 351, 631 (2006).
14. P. J. McLean et al., J. Neurochem. 83, 846 (2002).
15. P. J. McLean, H. Kawamata, B. T. Hyman, Neuroscience 104, 901 (2001).
16. W. Zhou, M. S. Hurlbert, J. Schaack, K. N. Prasad, C. R. Freed, Brain Res. 866, 33 (2000).
17. M. B. Feany, W. W. Bender, Nature 404, 394 (2000).
18. P. K. Auluck, H. Y. E. Chan, J. O. Trojanowski, V. M.-Y. Lee, N. M. Bonini, Science 295, 865 (2002); published online 20 December 2001 (10.1126/science.1067389).
19. M. Tanaka et al., J. Biol. Chem. 279, 4625 (2004).
20. E. Cohen, J. Bieschke, R. M. Perciavalle, J. W. Kelly, A. Dillin, Science 313, 1604 (2006); published online 9 August 2006 (10.1126/science.1124646).
21. P. H. Jensen et al., J. Biol. Chem. 275, 21500 (2000).
22. M. A. Alim et al., J. Alzheimers Dis. 6, 435 (2004).
23. Y. Kawaguchi et al., Cell 115, 727 (2003).
24. A. Iwata, B. E. Riley, J. A. Johnston, R. R. Kopito, J. Biol. Chem. 280, 40282 (2005).
25. J. P. Dompierre et al., J. Neurosci. 27, 3571 (2007).
26. Supported by a Tosteson postdoctoral fellowship award from Massachusetts Biomedical Research Corporation (T.F.O.), NIH grant 5P50-NS38372A-06 (B.T.H.), NIH grant R01-NS049221 (J.-C.R.), and a gift from Discovery of Novel Neurodegenerative Disease Therapeutics, MassGeneral Institute for Neurodegenerative Disease.